Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2938 in Seasonal Allergic Rhinitis
NCT07052097Phase 2Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQC2938 in seasonal allergic rhinitis (SAR), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jul 2025; status: completed.
02
Drugs
TQC2938
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07052097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052097.